The effects of the novel SHIP1 activator AQX‐1125 on allergen‐induced responses in mild‐to‐moderate asthma

SH2‐containing inositol‐5′‐phosphatase 1 (SHIP1) is an endogenous inhibitor of the phosphoinositide‐3‐kinase pathway that is involved in the activation and chemotaxis of inflammatory cells. AQX‐1125 is a first‐in‐class, oral SHIP1 activator with a novel anti‐inflammatory mode of action.

[1]  N. Gross.  The COPD Pipeline XXVII. , 2015, Chronic obstructive pulmonary diseases.

[2]  M. Silkey,et al.  Setipiprant, a selective CRTH2 antagonist, reduces allergen‐induced airway responses in allergic asthmatics , 2014, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[3]  C. Szabó,et al.  Characterization of AQX‐1125, a small‐molecule SHIP1 activator , 2013, British journal of pharmacology.

[4]  C. Szabó,et al.  Characterization of AQX‐1125, a small‐molecule SHIP1 activator , 2013, British journal of pharmacology.

[5]  R. Parry,et al.  Fine tuning T lymphocytes: a role for the lipid phosphatase SHIP-1. , 2010, Biochimica et biophysica acta.

[6]  Dave Singh,et al.  The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma , 2010, Respiratory research.

[7]  P. O'Byrne.  Allergen-induced airway inflammation and its therapeutic intervention , 2009, Allergy, asthma & immunology research.

[8]  C. Mitchell,et al.  The role of the inositol polyphosphate 5-phosphatases in cellular function and human disease. , 2009, The Biochemical journal.

[9]  D. Spina,et al.  PDE4 inhibitors: current status , 2008, British journal of pharmacology.

[10]  P. Barnes.  Immunology of asthma and chronic obstructive pulmonary disease , 2008, Nature Reviews Immunology.

[11]  A. Woodcock,et al.  Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma. , 2007, American journal of respiratory and critical care medicine.

[12]  S. Wenzel,et al.  Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies , 2007, The Lancet.

[13]  David E. Williams,et al.  Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells. , 2007, Blood.

[14]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[15]  M. Conti,et al.  Differential Expression and Function of Phosphodiesterase 4 (PDE4) Subtypes in Human Primary CD4+ T Cells: Predominant Role of PDE4D1 , 2007, The Journal of Immunology.

[16]  P. O'Byrne,et al.  The effects of inhaled budesonide and formoterol in combination and alone when given directly after allergen challenge. , 2007, The Journal of allergy and clinical immunology.

[17]  W. Busse,et al.  Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study , 2006, BMC pulmonary medicine.

[18]  P. Bardin,et al.  Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. , 2005, The Journal of allergy and clinical immunology.

[19]  D. Postma,et al.  Effect of low-dose ciclesonide on allergen-induced responses in subjects with mild allergic asthma. , 2005, The Journal of allergy and clinical immunology.

[20]  J. Cowan,et al.  Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. , 2005, The New England journal of medicine.

[21]  J. Lötvall,et al.  Differential effects of fluticasone and montelukast on allergen‐induced asthma , 2005, Allergy.

[22]  R. Pauwels,et al.  Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. , 2004, American journal of respiratory and critical care medicine.

[23]  G. Krystal,et al.  The Inositol 5′-Phosphatase SHIP-1 and the Src Kinase Lyn Negatively Regulate Macrophage Colony-stimulating Factor-induced Akt Activity* , 2003, Journal of Biological Chemistry.

[24]  S. Anderson,et al.  Indirect airway challenges , 2003, European Respiratory Journal.

[25]  H. Magnussen,et al.  Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma , 2002, European Respiratory Journal.

[26]  K. Ravichandran,et al.  Regulation of the immune response by SHIP. , 2002, Seminars in immunology.

[27]  P. O'Byrne,et al.  Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. , 2001, American journal of respiratory and critical care medicine.

[28]  G. Krystal,et al.  Lipid phosphatases in the immune system. , 2000, Seminars in immunology.

[29]  G. Krystal,et al.  Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. , 1998, Genes & development.

[30]  S. Holgate,et al.  The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. , 1997, The European respiratory journal.

[31]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[32]  F. Hargreave,et al.  Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. , 1996, American journal of respiratory and critical care medicine.